Florida Clinical Trials Report — April 2026

For Floridians considering participation in clinical research, April 2026 brings an urgent call to action, particularly for those interested in trials nearing their enrollment deadlines. Across the Sunshine State, 325 clinical trials are scheduled to close within the next 90 days. This includes a significant opportunity for individuals without specific health conditions, as 68 of these rapidly closing studies are still actively seeking healthy volunteers. If you've been contemplating contributing to medical advancements, now is a critical time to explore these options before they are no longer available.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various forms of cancer, neurological disorders, and respiratory issues are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Amyotrophic lateral sclerosis
• Traumatic brain injury
• Advanced solid tumor
• Myelodysplastic syndromes
• Metastatic cancer
• Metastatic breast cancer
• Myasthenia gravis
• Asthma

New Horizons: Major Trials and Healthy Volunteer Opportunities

This month, Florida welcomes 35 new clinical trials, offering fresh avenues for participation. While this number is a decrease from the 74 trials that opened in March 2026, the new studies include several high-profile initiatives from major sponsors, focusing on significant health challenges and innovative approaches.

Crucially, 9 of these new trials are actively seeking healthy volunteers, providing an excellent opportunity for individuals without specific medical conditions to contribute to research. Statewide, a total of 443 trials are currently recruiting healthy participants, underscoring the broad need for diverse involvement in medical progress.

Among the most notable new studies are several Phase 2 and 3 trials from leading pharmaceutical companies, alongside large-scale behavioral and diagnostic research:

• Novo Nordisk A/S is sponsoring two significant Phase 3 trials:
  • NCT07533175, "AMAZE 2," is investigating a new medicine, NNC0487-0111, for individuals with excess body weight and Type 2 diabetes. This large study aims to enroll 630 participants to evaluate the safety and effectiveness of this weekly injectable treatment.
  • NCT07509307, "AMAZE 6," also from Novo Nordisk A/S, is a Phase 3 study for 400 participants with excess body weight and knee osteoarthritis, evaluating NNC0487-0111's effect on weight loss and pain reduction.
• Incyte Corporation is launching NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants.
• Kinaset Therapeutics Inc is sponsoring NCT07532265, a Phase 2 dose-ranging study to evaluate the efficacy and safety of Frevecitinib (KN-002) in 512 patients with severe asthma not controlled by standard treatments.
• The University of South Florida is leading NCT07505381, a behavioral parent training intervention for caregivers of children aged 0-12 years, aiming to address early childhood disruptive behavior. This study plans to enroll 800 participants.
• RTI International is sponsoring NCT07527988, the "Safer Drinking Spaces Study," which will evaluate active bystander training provided to staff at alcohol-serving establishments. This large behavioral study seeks 3,180 participants.
• The Center for Violence Prevention Research Inc is launching NCT07526142, "Evaluation of Circles of Safety," a study to assess a child sexual abuse primary prevention strategy within youth sports. This significant initiative aims for 1,500 participants.
• Nicklaus Children's Hospital is conducting NCT07535294, a study to assess patient readiness for pelvic ultrasound using artificial intelligence technology to measure bladder volume. This diagnostic study plans to enroll 520 participants.

Florida's Research Footprint: Where to Find Trials

Florida continues to be a hub for clinical research, with a total of 3,788 trials currently recruiting across 195 cities and 4,654 research sites statewide. This broad distribution ensures accessibility for a wide range of residents.

This month's 35 new trials are concentrated in Florida's major metropolitan areas, making it convenient for residents in these regions to find participation opportunities. The cities with the most new trials include:

• Miami (12 new trials)
• Tampa (7 new trials)
• Jacksonville (6 new trials)
• Orlando (4 new trials)
• Gainesville (3 new trials)

Other cities like Naples, Gulf Breeze, Harbor Beach, Melbourne, and Miami Lakes also saw new trials open, indicating a statewide commitment to advancing medical science.

The conditions targeted by new trials this month are diverse, addressing both prevalent health issues and specific concerns. These include:

• Overweight
• Obesity
• Developmental disability
• AD-MCI (Alzheimer's Disease-Mild Cognitive Impairment)
• Asthma
• Behavior problem of childhood
• Alopecia areata
• Burning mouth syndrome
• Bystander intervention
• Child abuse sexual

Drug trials lead the way among new study types, accounting for 16 of the new initiatives. Behavioral interventions are also prominent with 8 new trials, followed by device studies (5), and other types of research.

Who Can Participate? Demographics and Sponsor Insights

Clinical trials in Florida are designed to be inclusive, welcoming participants from various demographic groups. Of the 35 new trials launched this month, 27 include older adults, ensuring that the senior population has ample opportunities to contribute to research relevant to their health needs. Additionally, 7 new trials are open to children, expanding options for younger participants. There are also specific opportunities for gender-focused research, with 3 new trials designed exclusively for female participants and 3 for male participants.

Both academic institutions and industry leaders are driving Florida's research landscape. Notable sponsors of new trials this month include:

• Mayo Clinic (3 new trials)
• Novo Nordisk A/S (2 new trials)
• University of South Florida (2 new trials)
• Eli Lilly and Company (2 new trials)
• AstraZeneca (2 new trials)

Overall, industry sponsors account for 18 of the new trials, while academic and other organizations contribute 17, highlighting a balanced and collaborative research environment.

As April draws to a close, the focus for Floridians interested in clinical research should be on the time-sensitive opportunities, particularly the 325 trials closing soon and the continued need for healthy volunteers. The coming months will undoubtedly bring further advancements, building on the diverse research initiatives launched this spring.